Randomised phase III study of copanlisib plus rituximab vs rituximab/placebo in ...
Dr Matthew Matasar - Memorial Sloan Kettering Cancer Center, NYC, US
16 Apr 2021
Reduced intensity allogeneic HSCT to hypomethylating therapy or best supportive ...
Dr Ryotaro Nakamura - City of Hope, California, USA
17 Feb 2021
OncoAlert and ecancer weekly roundup for February 01 - 06, 2021
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
9 Feb 2021
Emerging treatments for relapsed/refractory Hodgkin’s lymphoma in China
Dr Qingqing Cai - Sun Yat-Sen University, Guangzhou, China
29 Jan 2021
OncoAlert and ecancer weekly roundup for January 11 - 17, 2021
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
21 Jan 2021
Haematology updates from SIOG 2020
Dr Tanya Wildes - SIOG Science & Education Committee Chair
13 Jan 2021
The Burkitt lymphoma international prognostic index
Prof Adam Olszewski - Brown University, Providence, USA
24 Dec 2020
OncoAlert Colloquium Day 4: Gynae-oncology, lymphoma, sarcoma and melanoma
Dr Dizon, Dr Trent, Dr Cordoba, Dr Rolfo, Dr Haanen
23 Dec 2020
Results of venetoclax and azacitidine combination in chemotherapy ineligible unt...
Prof Hagop Kantarjian - MD Anderson Cancer Center, Houston, USA
22 Dec 2020
Long-term follow-up of low-intensity chemotherapy with combination therapy for r...
Prof Hagop Kantarjian - MD Anderson Cancer Center, Houston, USA
22 Dec 2020
Real-world evidence of the use of carfilzomib among multiple myeloma patients ac...
Prof Evangelos Terpos - University of Athens, Athens, Greece
22 Dec 2020
Real-world evidence of the use of carfilzomib to refractory to lenalidomide pati...
Prof Evangelos Terpos - University of Athens, Athens, Greece
22 Dec 2020
